Cargando…
Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) is a lethal malignancy lacking effective treatment. The Cyclin-dependent kinases 4/6 (CDK4/6) and PI3K/AKT signal pathways play pivotal roles in carcinogenesis and are promising therapeutic targets for HCC. Here we identified a new CDK4/6 and PI3K/AKT multi...
Autores principales: | Xia, Zhong-Kun, Wang, Wei, Qiu, Jian-Ge, Shi, Xi-Nan, Li, Hong-Jian, Chen, Rong, Ke, Kun-Bin, Dong, Chao, Zhu, Ying, Wu, Shi-Guo, Zhang, Rong-Ping, Meng, Zhuo-Ran, Zhao, Hui, Gu, Peng, Leung, Kwong-Sak, Wong, Man-Hon, Liu, Xiao-Dong, Zhou, Feng-Mei, Zhang, Jian-Ying, Yao, Ya-Ting, Wang, Si-Jia, Zhang, Chun-Yang, Qin, Yan-Ru, Lin, Marie Chia-mi, Jiang, Bing-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320333/ https://www.ncbi.nlm.nih.gov/pubmed/34335258 http://dx.doi.org/10.3389/fphar.2021.691769 |
Ejemplares similares
-
Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma
por: Zhu, Ying, et al.
Publicado: (2021) -
Ligustrazine protects against chronic hypertensive glaucoma in rats by inhibiting autophagy via the PI3K-Akt/mTOR pathway
por: Du, Hong-yan, et al.
Publicado: (2021) -
Ligustrazine induces viability, suppresses apoptosis and autophagy of retinal ganglion cells with ischemia/reperfusion injury through the PI3K/Akt/mTOR signaling pathway
por: Du, Hong-yan, et al.
Publicado: (2021) -
In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug
por: Shi, Xi-Nan, et al.
Publicado: (2015) -
Predicting associations among drugs, targets and diseases by tensor decomposition for drug repositioning
por: Wang, Ran, et al.
Publicado: (2019)